Nabriva Therapeutics plc (NBRV) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
Nabriva Therapeutics plc Fundamental Analysis
NBRV has had growing revenue for the last 2 years
Net Income Growth
NBRV has had growing net income for the last 4 years
Price to Book (PBV) Ratio
Undervalued price-to-book. NBRV stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER)
NBRV equity is higher than it's debt.
NBRV has positive revenue for last 4 years
Small market capitalization. Market capitalization is less than 2bn USD
NBRV never has positive net income for 2 years.
NBRV has low dividend yield (0%).
Return of Assets
NBRV has low return of asset (-98.4%).
Return of Equity
NBRV has low return of equity (-120.02%).
Return of Invested Capital
NBRV has low ROIC.
Nabriva Therapeutics plc Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 28,895,000 USD
- 52,163,000 USD
- Net Income
- -49,450,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -59,557,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-1.9x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||88.27%|
|Net Profit Margin (NPM)||-137.63%|
|Return of Assets (ROA)||-98.4%|
|Return of Equity (ROE)||-120.02%|
|Return on Capital Employed (ROCE)||-173.09%|
|Days of Sales Outstanding (DSO)||131.1|
|Days of Inventory Outstanding (DIO)||361.56|
|Days Payable Outstanding (DPO)||81.25|
|Operating Cycle (OC)||393.88|
|Cash Conversion Cycle (CCC)||139|
Nabriva Therapeutics plc Executives
- CEO Name
- Mr. Theodore Schroeder
Nabriva Therapeutics plc Profile
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
- Company name
- Nabriva Therapeutics plc
- NASDAQ Global Select
56 Fitzwilliam Square North